The NAGA Group AG: Growth path continues, record transactions and volumes in the current Q4. Hauck & Aufhäuser starts coverage and gives NAGA a 'BUY' rating and a target price of EUR 5.90.
10.12.2020 14:53:00 EET | Business Wire | Press release
The NAGA GROUP (XETRA: N4G, ISIN: DE000A161NR7), provider of the social network for financial market trading NAGA.com, reports sustained growth at a high level in the months of October and November on its digital trading platform NAGA.com.
The number of real money transactions is at a record level. With a total of 1.3 million transactions and new monthly records in October with 645,000 and November with 680,000 the Q4 figure will clearly surpass the record of Q3 2020 (1.5 million transactions). At the same time, the trading volume in the current fourth quarter has already exceeded EUR 25 billion (Q3 2020: EUR 33 billion) and will therefore also reach a record level.
"We are fully on track to achieve our annual targets. We are pleased that our investments in Marketing & Sales are bearing fruits and that we can continue to expand and improve our customer base, customer activity and the entire platform. NAGA has found a growth formula that enables it to grow in a precise way, fully, digitally and on a global level. The market potential is promising and the industry is growing - especially due to accelerated digitization, the topic of investing is more popular than ever", summarizes the CEO Benjamin Bilski.
NAGA GROUP AG also announces that the analysts from Hauck & Aufhäuser Research have started coverage of The NAGA GROUP share. Analyst Frederik Jarchow gives a buy recommendation with a price target of EUR 5.90. This corresponds to an upside potential of around 80%. In the initial study, Hauck & Aufhäuser particularly highlights the successful global rollout and digital marketing strategy and underlines the unique symbiosis of a trading and social media platform, which should lead to high YoY sales growth in the coming years and an increasing EBITDA margin.
The full research study is available for download on the website at www.ir.naga.com in the "Publications" section.
Bilski comments on the initial coverage: "We are delighted that Hauck & Aufhäuser Research started covering our share. It is one of the most renowned sources of information at hand which provides as objective as possible an assessment of our growth potential. The FinTech market is growing rapidly and the NAGA GROUP has all the characteristics to grow with it. It also confirms that we want to increase the transparency of our company and deal more intensively with investor relations. We are pleased that we can point out the future opportunities of the NAGA GROUP to other private and institutional investors on a wider scale."
NAGA GROUP also reports on the successful launch of the neo banking app NAGA Pay. The mobile digital bank and the card program recorded over 6,000 users and over EUR 2.5 million in transaction volume in the first 21 days after launch. The app offers users a free IBAN account as well as a Mastercard and a crypto wallet using fully digital onboarding. Shortly before Christmas, the stock trading feature will be released within the app. At the beginning of the year 2021, NAGA will officially start the promotion of the app.
###
About NAGA
NAGA is an innovative fintech company that has developed a socially enhanced financial system that creates a unified and seamless experience across personal finance and investing. Its proprietary platform offers a range of products ranging from trading, investing, and cryptocurrencies to a physical Mastercard and social investing features such as a Feed, a Messenger and Auto-Copy. NAGA is a synergistic all-in-one solution that's accessible and inclusive, and that provides a better way to trade, invest, connect, earn, acquire and pay, across both fiat and crypto.
| Language: | English |
| Company: | The NAGA Group AG |
| Hohe Bleichen 12 | |
| 20354 Hamburg | |
| Germany | |
| E-mail: | info@naga.com |
| Internet: | www.naga.com |
| ISIN: | DE000A161NR7 |
| WKN: | A161NR |
| Indices: | Scale 30 |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Hamburg, Munich, Stuttgart, Tradegate Exchange |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201210005476/en/
Contact information
Benjamin Bilski
Tel:+49-(0)40-5247-79153
Email:ben@naga.com
ingo.janssen@ubj.de
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Huawei, LG Electronics and Nokia Named as Founder Licensors of New Sisvel POS Pool1.4.2026 13:17:00 EEST | Press release
Three world-class innovators are the founder licensors of the new Point of Sale (POS) patent pool, covering 2G to 5G technology, which Sisvel has launched today. Huawei, LG Electronics and Nokia have made their standard essential patents (SEPs) reading on cellularly connected POS devices available through the programme, so simplifying access to the increasingly ubiquitous technology. Early participation incentives for licensors to join the pool are available until mid-May. Other cellular patent owners not currently in discussions with Sisvel are encouraged to get in touch. Ranging from handheld card machines to tablet-based registers, POS devices have transformed customer payment processing. Increasingly, they also offer enhanced capabilities such as inventory management, real-time tracking, advanced analytics and automatic re-ordering. Standardised cellular technology is the critical feature that enables POS terminals to function wherever customers are located. The Sisvel POS programm
Mosaic Therapeutics appoints Dr Vince O'Neill, MD, as Head of R&D1.4.2026 12:11:00 EEST | Press release
Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company developing next-generation, Synergistic Precision combination therapies, today announced the appointment of Dr Vince O’Neill as Head of Research and Development (R&D) to support its next phase of growth. “We are delighted to welcome Vince to the Mosaic leadership team at this pivotal stage of the company’s evolution,”said Thomas Fuchs, CEO, Mosaic Therapeutics.“His deep expertise in targeted oncology drug development and diagnostics will be instrumental as we advance our pipeline to bring transformative therapies to patients in need.” Vince is a board-certified medical oncologist and highly experienced biotechnology executive, bringing over two decades of therapeutic and diagnostic R&D experience within industry to Mosaic Therapeutics, with a track record spanning from IND through to NDA/BLA/MAA approval. Most recently he served at BioXcel Therapeutics as EVP, Head of Product Developme
The AI Summit London Launches Strategic Partnerships with London Business School and General Purpose to Ignite New Era in AI Leadership1.4.2026 10:00:00 EEST | Press release
The AI Summit London, the conference where commercial AI comes to life, has announced strategic collaborations with London Business School and General Purpose to introduce two dedicated AI Training programmes, taking place ahead of the conference on 9 June. Drawing upon the globally recognised expertise in executive education at the London Business School’s Data Science & AI Initiative (DSAI), the one-day AI Leadership Accelerator is a high-impact session designed to equip senior business leaders with the knowledge and tools to unlock real and profitable value from AI. The DSAI at London Business School helps leaders make sense of AI in a way that goes beyond the hype, focusing on what it really means for their organisations, industries, and competitive positioning. Drawing on rigorous, cross-disciplinary research, DSAI provides clear, evidence-based insights - equipping executives with the perspective needed to make confident, high-stakes decisions. “Through our work we increasingly s
Samsung Research Reveals Over Half of Europeans Admit to Looking at a Stranger's Phone Screen in Public – With Nearly a Quarter Doing so out of Sheer Curiosity1.4.2026 09:00:00 EEST | Press release
As millions of Europeans2 get ready to enjoy the Easter weekend, new research from Samsung finds Europe’s public spaces have become shared screens: 56% of people say they have accidentally looked at a stranger’s phone, citing public transport as the most likely place to notice someone else’s screen (57%). Nearly one in four Europeans2 (24%) admit to looking at someone else’s phone out of curiosity, exposing a stream of private content from personal photos to bank details. Samsung Electronics surveyed 11,000 Europeans2 to support the launch of the Galaxy S26 Ultra, which introduces a built-in Privacy Display. This new hardware-based technology keeps screen content visible only from the front to protect privacy from side angles, without compromising the viewing experience3. The study further reveals a gap between perceived phone privacy and reality: While 48%* feel their own phone use is private when using it in crowded places, 52%** find it easy to view someone else’s screen in public.
RevolKa Reimagines Antibody Engineering with "RevoAb ® "1.4.2026 07:30:00 EEST | Press release
RevolKa Ltd. (RevolKa), a venture-backed biotech company providing an advanced AI protein engineering technology platform, called aiProtein®, is pleased to announce the official global launch of RevoAb®, an innovative and quick online service for antibody sequence optimization to solve challenges in physicochemical properties, especially antibodyyields. RevoAb®:The Next-Gen AI Antibody Design Since December 2023, RevolKa has provided an antibody optimization services utilizing aiProtein®. The newly launched RevoAb® is a quick intuitive online antibody sequence optimization service that integrates RevolKa’s core technology—the "Refined Naturalness Framework Engineering". RevoAb® is designed to generate antibody framework sequences optimized for improved physicochemical properties, especially protein expression levels, without trade-off of affinity. This allows researchers worldwide to experience RevolKa’s high-performance antibody design. Key Advantages of RevoAb® Speed: Multiple optimi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom